Merck, VA sales and marketing update

Merck said the U.S. Department of Veterans Affairs added Zepatier grazoprevir/elbasvir ( MK-5172/MK-8742) to the VA National Formulary. In January, FDA approved Zepatier to treat HCV genotype 1 and 4 infection. Merck said about 180,000 veterans have chronic HCV infection. The VA covers about 15% of the U.S. HCV genotype 1 infection market. ...